Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

NCT04336943 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Biochemically Recurrent Prostate Carcinoma
Prostate Adenocarcinoma

Interventions

BIOLOGICAL: Durvalumab
DRUG: Olaparib
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

University of Washington

Collaborators

[object Object]